Back to today’s briefing

Story perspectives

Immunotherapy DOC1021 Shows 88% Survival in Glioblastoma Trials

6/3/2025

31 3

Summary

Story summary

At the 2025 ASCO Annual Meeting in Chicago, Diakonos Oncology unveiled groundbreaking phase 1 trial results for DOC1021, an immunotherapy targeting glioblastoma, boasting an impressive 88% survival rate after 12 months. Dr. Laura Aguilar expressed excitement about broadening this innovative treatment to other cancers, including ongoing trials for pancreatic cancer and future plans for refractory melanoma.

1 of 1

Story summary

At the 2025 ASCO Annual Meeting in Chicago, Diakonos Oncology unveiled groundbreaking phase 1 trial results for DOC1021, an immunotherapy targeting glioblastoma, boasting an impressive 88% survival rate after 12 months. Dr. Laura Aguilar expressed excitement about broadening this innovative treatment to other cancers, including ongoing trials for pancreatic cancer and future plans for refractory melanoma.